Inhibrx Biosciences, Inc.
INBX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002007919
In the last 90 days, Inhibrx Biosciences, Inc. insiders filed 6 open-market purchases and 2 sales; 162 institutions reported holding it in 13F filings for Q2 2026, worth $1.36B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Inhibrx Biosciences, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 107
- −1 vs. Q1 2023
- Shares held
- 36.0M
- −646.5K (−1.8%) vs. Q1 2023
- Total value
- $935.2M
- +$243.5M (+35.2%) vs. Q1 2023
- New holders
- 15
- 39 more added
- Sold out
- 16
- 30 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INBX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 162 | $1.36B |
| Q1 2026 | 135 | $854.6M |
| Q4 2025 | 138 | $1.01B |
| Q3 2025 | 102 | $353.6M |
| Q2 2025 | 89 | $148.9M |
| Q1 2025 | 92 | $151.0M |
| Q4 2024 | 101 | $171.9M |
| Q3 2024 | 96 | $139.3M |
| Q2 2024 | 88 | $137.9M |
| Q1 2024 | 126 | $1.34B |
| Q4 2023 | 126 | $1.54B |
| Q3 2023 | 111 | $716.1M |
| Q2 2023 | 107 | $935.2M |
| Q1 2023 | 108 | $691.6M |
| Q4 2022 | 116 | $886.0M |
| Q3 2022 | 102 | $512.2M |
| Q2 2022 | 100 | $297.3M |
| Q1 2022 | 99 | $548.0M |
| Q4 2021 | 101 | $1.01B |
| Q3 2021 | 66 | $681.6M |
| Q2 2021 | 61 | $538.8M |
| Q1 2021 | 55 | $326.3M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Inhibrx Biosciences, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 1,771,540 | $46.0M | 0.00% | −3,741−0.2% | Reduced |
| FMR LLC | 1,771,732 | $46.0M | 0.00% | +162,705+10.1% | Added |
| State Street Corp | 1,817,416 | $47.2M | 0.00% | −258,574−12.5% | Reduced |
| BlackRock Inc. | 2,546,603 | $66.1M | 0.00% | +213,678+9.2% | Added |
| Perceptive Advisors LLC | 3,624,182 | $94.1M | 2.73% | +8,799+0.2% | Added |
| Ra Capital Management, L.P. | 3,853,867 | $100.0M | 1.89% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 6,639,199 | $172.4M | 0.71% | 00.0% | Unchanged |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −1,192,281−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −92,107−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −63,931−100.0% | Sold out |
| Twinbeech Capital LP | 0 | $0 | 0.00% | −57,095−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −44,541−100.0% | Sold out |
| Los Angeles Capital Management LLC | 0 | $0 | 0.00% | −30,823−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −25,509−100.0% | Sold out |
| Vident Investment Advisory, LLC | 0 | $0 | 0.00% | −25,199−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −18,186−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −15,788−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −15,163−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −11,214−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,369−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −10,020−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −8,927−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −547−100.0% | Sold out |